{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126240","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.572364+00:00","generated_at":"2026-05-15T08:53:24.761031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rani Therapeutics reports Q4 net loss of $9.1M; announces up to $1.085B Chugai collaboration and $60.3M placement","bullets":["Collaboration with Chugai for up to $1.085B to develop oral therapy using RaniPill; Chugai may expand to 5 additional targets.","Raised $60.3M via oversubscribed private placement led by Samsara BioCapital, including $6.0M debt conversion.","Initiated Phase 1 study of RT-114 (oral GLP-1/GLP-2 dual agonist) via RaniPill for obesity in December 2025.","Cash and equivalents $49.7M as of Dec 31, 2025; expected to fund operations into Q4 2027, including Chugai milestone.","Net loss for FY2025 was $41.0M, narrowed from $56.6M in FY2024; R&D expenses decreased 24% to $20.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126240","json":"https://secwatch.observer/filing/0001193125-26-126240.json","markdown":"https://secwatch.observer/filing/0001193125-26-126240.md","text":"https://secwatch.observer/filing/0001193125-26-126240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/0001193125-26-126240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/rani-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:53:24.761031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"531f6c09cf9db410ce97930225f2cc13a728d6bf","claim":"Rani Therapeutics Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: revenue $1.5 million.","evidence_excerpt":"to the Chugai agreement, to be sufficient to fund its operations into the fourth quarter of 2027. • Contract revenue for the three and twelve months ended December 31, 2025 were $1.5 million and $1.6 million, respectively. Of this, $1.5 million was attributed to a License and Collaboration Agreement and $0.1 million was attributed to evaluation services performed for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/0001193125-26-126240-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2025"},{"label":"Revenue","value":"$1.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}